• LINAGLIP-M is a combination medication available in three formulations:

LINAGLIP-M with Linagliptin 2.5 mg + Metformin 500 mg Tablets

LINAGLIP-M with Linagliptin 2.5 mg + Metformin 850 mg Tablets

LINAGLIP-M with Linagliptin 2.5 mg + Metformin 1000 mg Tablets

• The combination includes the active ingredients Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Metformin, a biguanide.
• The medication is manufactured by Asian Pharmaceuticals.
• LINAGLIP-M is commonly prescribed for individuals with type 2 diabetes to improve glycemic control through dual mechanisms: by increasing insulin sensitivity with Metformin and by inhibiting the breakdown of incretin hormones with Linagliptin.